It's good to see a brief mention of Breathtec and Na-Nose as one from a news outlet. Hopefully management will aggressively pair the two with future news outlets utilizing on the ground information. Breathtec is at the clinical trial phase without traction. Maybe a new video that targets our clinical advancement towards the following diseases will do shareholders some justice:
The licensed technology will be clinically evaluated as a non-invasive point of care device for early detection of community and hospital based infections such as Streptococcus; Methicillin resistant (MRSA); Staphylococcus; Enterococcus; Vancomycin resistant (VRE); Pneumococcus; Hemophilus influenza (HiB); Chickenpox; and the common cold, etc.
News 
Market Data 
Discover 
